— Know what they know.
Not Investment Advice

TBIO OTC

Telesis Bio, Inc.
1W: -99.1% 1M: -90.0% 3M: -99.8% YTD: -99.8% 1Y: -99.2% 3Y: -100.0% 5Y: -100.0%
$0.00
+0.00 (+0.00%)
 
OTC · Healthcare · Medical - Devices · Tech Score Sell · Power 44 · $7839 mcap · 59M float · 0.0007% daily turnover · Short 27% of daily vol
Smart Money Score
No convergence signal
Key Statistics
Market Cap$0.0M
52W Range0.000099999997-0.15
Volume3
Avg Volume415
Beta2.47
Dividend—
Analyst Ratings
8 Buy 6 Hold 0 Sell
Consensus Buy
Company Info
CEOEric Esser
Employees39
SectorHealthcare
IndustryMedical - Devices
IPO Date2021-06-18
10431 Wateridge Circle
San Diego, CA 92121-2993
US
16179457361
About Telesis Bio, Inc.

Telesis Bio, Inc., formerly known as Codex DNA, Inc. (and SGI-DNA, Inc. prior to that), is a San Diego, California-based synthetic biology company established in 2011. The company provides a comprehensive suite of instruments, reagents, and services for synthetic biology applications, catering primarily to pharmaceutical and academic laboratories worldwide. Its clientele also extends to government institutions, contract research organizations (CROs), and other synthetic biology enterprises. Among its core offerings is the BioXp system, a groundbreaking platform that empowers researchers to generate endpoint-ready synthetic DNA directly from digital sequences. Complementing this, the BioXp portal offers an intuitive online environment with guided workflows and design tools for constructing new DNA sequences and assembling them into desired vectors. For specific synthetic biology tasks, Telesis Bio supplies BioXp kits, which include essential building blocks and proprietary reagents like its well-known Gibson Assembly products. Additional solutions encompass cloud-based scripts and specialized benchtop reagents designed for post-BioXp system workflows. Through its Biofoundry Services, customers can commission and receive BioXp system-generated products, such as custom genes, clones, cell-free amplified DNA, and diverse variant libraries. The company also performs enzymatic DNA synthesis using short oligo ligation assembly techniques.

Latest News
No recent news

Recent Insider Trades

NameTypeSharesPriceDate
Krueger Todd A-Award 8,390 — 2024-07-24
Krueger Todd A-Award 5,268 $4.10 2024-07-24
Golub Steven J A-Award 8,390 — 2024-07-24
Golub Steven J A-Award 5,268 $4.10 2024-07-24
Hlavinka Sarah E. A-Award 8,390 — 2024-07-24

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms